Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

Christine M. Parseghian(The University of Texas MD Anderson Cancer Center), Scott Kopetz(The University of Texas MD Anderson Cancer Center), John H. Strickler(Duke Medical Center), Benny Johnson(The University of Texas MD Anderson Cancer Center), Van K. Morris(The University of Texas MD Anderson Cancer Center), X Liu(The University of Texas MD Anderson Cancer Center), Richard B. Lanman(C.T. de Wit Graduate School for Production Ecology and Resource Conservation), Arvind Dasari(The University of Texas MD Anderson Cancer Center), David S. Hong(The University of Texas MD Anderson Cancer Center), Ryan B. Corcoran(Massachusetts General Hospital), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Naveen Garg(The University of Texas MD Anderson Cancer Center), Kimberly C. Banks(Guardant (United States)), Eduardo Vilar(The University of Texas MD Anderson Cancer Center), Bryan K. Kee(The University of Texas MD Anderson Cancer Center), Jingjing Wu(The University of Texas MD Anderson Cancer Center), AmirAli Talasaz(Guardant (United States)), Jonathan M. Loree(University of British Columbia), Jason T. Henry(Sarah Cannon Research Institute), Allan Andresson Lima Pereira(The University of Texas MD Anderson Cancer Center), Katherine Clifton(The University of Texas MD Anderson Cancer Center), Michael J. Overman(The University of Texas MD Anderson Cancer Center), Victoria M. Raymond(Guardant (United States)), Stefania Napolitano(The University of Texas MD Anderson Cancer Center)
Annals of Oncology
November 17, 2018
10.1093/annonc/mdy509
Cited by 239

Related Papers

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
|Nature Communications|2017|999
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
|Annals of Oncology|2017|591